Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluocinolone acetonide - ANI Pharmaceuticals/EyePoint Pharmaceuticals

Next Previous
Drug Profile

Fluocinolone acetonide - ANI Pharmaceuticals/EyePoint Pharmaceuticals

Alternative Names: DF-277; FAI insert; Fluocinolone; Fluocinolone acetonide intravitreal implant; Fluocinolone acetonide intravitreal insert; Fluocinolone acetonide micro-insert intravitreous implant - Alimera/EyePoint Pharmaceuticals; ILUVIEN; Iluvien; Injectable micro-insert - Alimera Sciences/EyePoint Pharmaceuticals; Medidur implant; Medidur-FA; NSC-92339; Ophthalmic implant - Alimera Sciences/EyePoint Pharmaceuticals; OT-401; OT-703; YUTIQ; YUTIQ50

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator pSivida Inc
  • Developer Alimera Sciences; ANI Pharmaceuticals; EyePoint Pharmaceuticals; Horus Pharma; Hospital for Special Surgery; Johns Hopkins University; Ocumension Therapeutics; pSivida Inc; Specialised Therapeutics Australia
  • Class Anti-inflammatories; Antipruritics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Pregnadienes; Small molecules; Vasoconstrictors
  • Mechanism of Action Glucocorticoid receptor agonists; Nitric oxide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetic macular oedema; Uveitis
  • Phase II Retinal vascular occlusion; Wet age-related macular degeneration
  • No development reported Osteoarthritis

Most Recent Events

  • 28 May 2025 No recent reports of development identified for preclinical development in Diabetic-macular-oedema in China (Intravitreous, Implant)
  • 14 Mar 2025 Registered for Uveitis in USA (Intravitreous)
  • 14 Mar 2025 ANI Pharmaceuticals plans to begin marketing ILUVIEN in the US under the expanded label in 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top